Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Key House Medicare Subcommittee Will Have New Leaders; Rep. Stark Loses Election Bid

Executive Summary

Rep. Pete Stark, D-Calif., often a critic of the pharmaceutical industry, lost his re-election bid, leaving the top Democratic spot open on the Ways and Means Committee’s Health Subcommittee. Subcommittee Chairman Wally Herger already planned to retire. All members of the Senate HELP and Finance Committees up for re-election won their races.

You may also be interested in...

Reps. Brady, McDermott Trade For Ways And Means Health Panel Posts

The top posts of the House Ways and Means Committee’s Health Subcommittee will be taken over by newcomers to the panel, with Kevin Brady, R-Texas, as chairman and Jim McDermott, D-Wash., as ranking member.

Senate Elections 2012: Former HHS Chief Thompson Could Return To Washington As Senator

Polls show Tommy Thompson, HHS secretary from 2001 to 2005, leading in the Wisconsin Senate race. His experience in health care could make him a fit for the Finance Committee or the Health, Education, Labor and Pensions Committee. Few members of HELP are planning to leave at the end of the session, but a number of retirements on Finance could leave space for newcomers.

Medicare Reform Using Part D Model Is Advocacy Priority For PhRMA – Castellani

For PhRMA, supporting a move toward privatizing Medicare is a tactic that may help avoid the establishment of new price controls in the system, like the often-discussed mandated drug rebates in Part D.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts